Electrodesiccation and Curettage for Squamous Cell Carcinoma in Situ: The Effect of Anatomic Location on Local Recurrence.
Journal
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
ISSN: 1524-4725
Titre abrégé: Dermatol Surg
Pays: United States
ID NLM: 9504371
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
31
8
2023
pubmed:
6
6
2023
entrez:
6
6
2023
Statut:
ppublish
Résumé
Electrodesiccation and curettage (EDC) is a common, minimally invasive treatment of cutaneous squamous cell carcinoma in situ (SCCIS). Determine the 5-year recurrence rate of EDC for SCCIS and to determine if this differs by anatomic location. A retrospective, single-center, cohort study of patients treated between January 1, 2000, and January 1, 2017, with at least 5 years of follow-up. The overall 5-year recurrence rate of EDC for SCCIS was calculated and compared across low-risk (L), moderate-risk (M), and high-risk (H) anatomic zones. Five hundred ten tumors were randomly identified from 367 unique patients. The 5-year recurrence rate of the entire cohort was 5.3%. There was no significant difference in recurrence by clinical size or immunosuppressed status. One hundred thirty-four tumors in the L zone were matched 1:1:1 to tumors in the M and H zones. The 5-year recurrence rate of M zone tumors (8.2%) and H zone tumors (6.0%) were higher than the recurrence rate of a L zone tumors (3.0%), but this was not statistically significant ( p = .075 and p = .247, respectively). Electrodesiccation and curettage allows for a high 5-year cure rate across a broad range of anatomic sites. However, overall cure rate should be individualized by anatomic location when counseling patients.
Sections du résumé
BACKGROUND
Electrodesiccation and curettage (EDC) is a common, minimally invasive treatment of cutaneous squamous cell carcinoma in situ (SCCIS).
OBJECTIVE
Determine the 5-year recurrence rate of EDC for SCCIS and to determine if this differs by anatomic location.
METHOD AND MATERIALS
A retrospective, single-center, cohort study of patients treated between January 1, 2000, and January 1, 2017, with at least 5 years of follow-up. The overall 5-year recurrence rate of EDC for SCCIS was calculated and compared across low-risk (L), moderate-risk (M), and high-risk (H) anatomic zones.
RESULTS
Five hundred ten tumors were randomly identified from 367 unique patients. The 5-year recurrence rate of the entire cohort was 5.3%. There was no significant difference in recurrence by clinical size or immunosuppressed status. One hundred thirty-four tumors in the L zone were matched 1:1:1 to tumors in the M and H zones. The 5-year recurrence rate of M zone tumors (8.2%) and H zone tumors (6.0%) were higher than the recurrence rate of a L zone tumors (3.0%), but this was not statistically significant ( p = .075 and p = .247, respectively).
CONCLUSION
Electrodesiccation and curettage allows for a high 5-year cure rate across a broad range of anatomic sites. However, overall cure rate should be individualized by anatomic location when counseling patients.
Identifiants
pubmed: 37279310
doi: 10.1097/DSS.0000000000003855
pii: 00042728-990000000-00419
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-824Informations de copyright
Copyright © 2023 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.
Références
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015;151:1081–6.
Kao GF. Carcinoma arising in Bowen's disease. Arch Dermatol 1986;122:1124–6.
Bath-Hextall FJ, Matin RN, Wilkinson D, Leonardi-Bee J. Interventions for cutaneous Bowen's disease. Cochrane database Syst Rev. 2013;2013:CD007281.
Chren MM, Linos E, Torres JS, Stuart SE, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013;133:1188–96.
Stewart JR, Lang ME, Brewer JD. Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: a systematic review and meta-analysis. J Am Acad Dermatol 2022;87:131–7.
Matsumoto AJ, Schmitt AR, Skelley LM, Baum CL. Factors influencing squamous cell carcinoma in situ recurrence and implications for treatment choice. Dermatol Surg 2018;44:613–20.
Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery [published correction appears in J Am Acad Dermatol. 2015 Apr;72(4):748]. J Am Acad Dermatol 2012;67:531–50.
Leitenberger JJ, Rogers H, Chapman JC, Maher IA, et al. Defining recurrence of nonmelanoma skin cancer after Mohs micrographic surgery: report of the American College of Mohs Surgery Registry and outcomes committee. J Am Acad Dermatol 2016;75:1022–31.
Wysong A, Higgins S, Blalock TW, Ricci D, et al. Defining skin cancer local recurrence. J Am Acad Dermatol 2019;81:581–99.
Diaz-Cascajo C, Borghi S, Weyers W, Bastida-Inarrea J. Follicular squamous cell carcinoma of the skin: a poorly recognized neoplasm arising from the wall of hair follicles. J Cutan Pathol 2004;31:19–25.
Christensen SR, McNiff JM, Cool AJ, Aasi SZ, et al. Histopathologic assessment of depth of follicular invasion of squamous cell carcinoma (SCC) in situ (SCCis): implications for treatment approach. J Am Acad Dermatol 2016;74:356–62.
Leibovitch I, Huilgol SC, Selva D, Hill D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005;53:253–60.
Prickett KA, Ramsey ML. Mohs micrographic surgery. In: StatPearls. Treasure Island, FL: StatPearls Publishing; pp. 2022.
Carley SK, Dixon A, Zachary CB, Steinman HK. Revised Mohs surgery care guidelines for squamous cell carcinoma in-situ are overdue. Dermatol Online J 2019;25:13030.
Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, et al. Field cancerization: definition, epidemiology, risk factors, and outcomes. J Am Acad Dermatol 2020;83:709–17.